Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
34
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Regulus Therapeutics Inc market cap is $564.95M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Regulus Therapeutics Inc 52 week high is $8.35 as of November 21, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Regulus Therapeutics Inc 52 week low is $0.8301 as of November 21, 2026.
Regulus Therapeutics Inc stock price today is $8.16.
Regulus Therapeutics Inc stock price yesterday was $8.14.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Regulus Therapeutics Inc's P/E ratio is -11.23.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Regulus Therapeutics Inc P/B ratio is 7.8361.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Regulus Therapeutics Inc 50-day moving average is $7.51.